SI-BONE Valuation
Is SIBN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of SIBN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von SIBN für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von SIBN für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SIBN?
Other financial metrics that can be useful for relative valuation.
What is SIBN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$632.39m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.6x |
Enterprise Value/EBITDA | -12.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SIBN's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.2x | ||
SILK Silk Road Medical | 3.9x | 9.8% | US$664.0m |
IRMD IRADIMED | 8.2x | 10.0% | US$522.3m |
OFIX Orthofix Medical | 0.7x | 6.7% | US$530.8m |
FNA Paragon 28 | 4x | 15.2% | US$844.9m |
SIBN SI-BONE | 4.5x | 15.1% | US$632.4m |
Price-To-Sales gegen Gleichaltrige: SIBN ist auf der Grundlage des Price-To-Sales Verhältnisses (6x) im Vergleich zum Durchschnitt der Vergleichsgruppe (2.3x) teuer.
Price to Earnings Ratio vs Industry
How does SIBN's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales gegen Industrie: SIBN ist teuer, wenn man sein Price-To-Sales Verhältnis (6x) mit dem US Medical Equipment Branchendurchschnitt (3.2x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is SIBN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.5x |
Fair PS Ratio | 4.1x |
PM vs. Fair Ratio: SIBN ist teuer auf der Grundlage des Verhältnisses Price-To-Sales (6x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (4.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | US$15.36 | US$26.67 +73.6% | 9.4% | US$32.00 | US$24.00 | n/a | 9 |
Mar ’25 | US$17.08 | US$26.88 +57.3% | 9.6% | US$32.00 | US$24.00 | n/a | 8 |
Feb ’25 | US$20.64 | US$27.00 +30.8% | 9.1% | US$32.00 | US$25.00 | n/a | 8 |
Jan ’25 | US$20.99 | US$26.38 +25.7% | 10.5% | US$32.00 | US$24.00 | n/a | 8 |
Dec ’24 | US$18.82 | US$25.63 +36.2% | 13.1% | US$32.00 | US$22.00 | n/a | 8 |
Nov ’24 | US$17.26 | US$28.38 +64.4% | 12.2% | US$32.00 | US$22.00 | n/a | 8 |
Oct ’24 | US$21.24 | US$30.63 +44.2% | 5.6% | US$33.00 | US$27.00 | n/a | 8 |
Sep ’24 | US$22.61 | US$30.63 +35.4% | 5.6% | US$33.00 | US$27.00 | n/a | 8 |
Aug ’24 | US$25.68 | US$30.75 +19.7% | 6.5% | US$33.00 | US$27.00 | n/a | 8 |
Jul ’24 | US$26.98 | US$29.50 +9.3% | 7.0% | US$33.00 | US$27.00 | n/a | 8 |
Jun ’24 | US$25.23 | US$28.88 +14.4% | 5.6% | US$32.00 | US$27.00 | n/a | 8 |
May ’24 | US$22.60 | US$24.29 +7.5% | 14.2% | US$32.00 | US$20.00 | n/a | 7 |
Apr ’24 | US$19.67 | US$24.29 +23.5% | 14.2% | US$32.00 | US$20.00 | US$15.78 | 7 |
Mar ’24 | US$20.01 | US$24.50 +22.4% | 13.4% | US$32.00 | US$20.00 | US$17.08 | 8 |
Feb ’24 | US$17.05 | US$21.63 +26.8% | 19.7% | US$32.00 | US$17.00 | US$20.64 | 8 |
Jan ’24 | US$13.60 | US$22.13 +62.7% | 18.8% | US$32.00 | US$17.00 | US$20.99 | 8 |
Dec ’23 | US$12.68 | US$22.75 +79.4% | 16.6% | US$32.00 | US$20.00 | US$18.82 | 8 |
Nov ’23 | US$18.68 | US$24.13 +29.1% | 20.7% | US$36.00 | US$20.00 | US$17.26 | 8 |
Oct ’23 | US$17.46 | US$24.57 +40.7% | 21.0% | US$36.00 | US$20.00 | US$21.24 | 7 |
Sep ’23 | US$16.59 | US$24.57 +48.1% | 21.0% | US$36.00 | US$20.00 | US$22.61 | 7 |
Aug ’23 | US$13.73 | US$24.14 +75.8% | 25.8% | US$36.00 | US$17.00 | US$25.68 | 7 |
Jul ’23 | US$13.60 | US$25.43 +87.0% | 20.6% | US$36.00 | US$20.00 | US$26.98 | 7 |
Jun ’23 | US$14.53 | US$25.43 +75.0% | 20.6% | US$36.00 | US$20.00 | US$25.23 | 7 |
May ’23 | US$19.98 | US$32.29 +61.6% | 9.0% | US$36.00 | US$28.00 | US$22.60 | 7 |
Apr ’23 | US$22.74 | US$33.29 +46.4% | 12.7% | US$41.00 | US$28.00 | US$19.67 | 7 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, und die Analysten liegen in einem statistisch sicheren Bereich der Übereinstimmung.